Bladder Cancer

Share this journal
Bladder-Cancer-Cover-FINAL-72dpi-rgb
ISSN print
2352-3727
ISSN online
2352-3735
Volume
1; 2 issues
Status
First issue published on 4 May 2015
Next issue
1:2 scheduled for October 2015
Subject
Cancer Research, Urology
INSTITUTIONAL SUBSCRIPTION FOR 2015 (PRINT ONLY) €120 / US$158 Excluding VAT
Subscribe

Bladder Cancer Launch Issue Now Live
We are delighted to announce the publication of the launch issue of Bladder Cancer (BLC), the first journal dedicated to the disease. The launch issue is freely available here.

Follow Bladder Cancer on Twitter and Facebook
We are pleased to inform you that Bladder Cancer now has its own Twitter account and Facebook page. Matthew Nielsen and Angela B. Smith have agreed to act as Social Media Editors. They will be responsible for selecting and posting news of interest to the bladder cancer research community. Follow us on Twitter and Facebook!

Bladder Cancer is an international multidisciplinary journal to facilitate progress in understanding the epidemiology/etiology, genetics, molecular correlates, pathogenesis, pharmacology, ethics, patient advocacy and survivorship, diagnosis and treatment of tumors of the bladder and upper urinary tract. The journal publishes research reports, reviews, short communications, and letters-to-the-editor. In addition, the journal will also have a “News and Views” section for timely commentary. The journal is dedicated to providing an open forum for original research in basic science, translational research and clinical medicine that will expedite our fundamental understanding and improve treatment of tumors of the bladder and upper urinary tract.

Editors-in-Chief

Seth P. Lerner
Scott Department of Urology
Baylor College of Medicine
Houston, Texas, USA
Email: blc@iospress.com

Dan Theodorescu
University of Colorado Cancer Center
Aurora, Colorado, USA
Email: blc@iospress.com

Associate Editors for Reviews

Georgios Gakis
University Hospital Tübingen, Tübingen, Germany

Matthew Galsky 
Mount Sinai Hospital, New York, USA

Associate Editors

Joaquim Bellmunt
Dana-Farber Cancer Institute, Harvard Medical School, Boston, USA

Jason A. Efstathiou
Massachusetts General Hospital, Harvard Medical School, Boston, USA

Donna Hansel
University of California, San Diego, San Diego, USA

Maha Hussain
University of Michigan, Ann Arbor, USA

Cheryl Lee
University of Michigan, Ann Arbor, USA

David McConkey
The University of Texas MD Anderson Cancer Center, Houston, USA

Matt Milowsky
University of North Carolina, Chapel Hill, USA

Torben Ørntoft 
Aarhus University Hospital, Aarhus, Denmark

Diane Zipursky Quale
Bladder Cancer Advocacy Network (BCAN), Bethesda, USA

Francisco X. Real
CNIO, Madrid, Spain

George Thalmann
University of Bern, Bern, Switzerland

Xue-Ru Wu
New York University (NYU), New York, USA

Alexandre R. Zlotta
Mount Sinai Hospital, Toronto, Canada
Princess Margaret Cancer Centre, University Health Network, Toronto, Canada

Ellen Zwarthoff
Erasmus MC, Rotterdam, The Netherlands

Editors of Clinical Trials Corner

Piyush K. Agarwal
National Cancer Institute, Bethesda, USA

Cora N. Sternberg
San Camillo and Forlanini Hospitals, Roma, Italy

Social Media Editors

Matthew Nielsen
University of North Carolina, Chapel Hill, USA

Angela B. Smith
University of North Carolina, Chapel Hill, USA

Editorial Board

Cory Abate-Shen
Columbia University Medical Center, New York, USA

Hikmat Al-Ahmadie
Memorial Sloan-Kettering Cancer Center, New York, USA

Matthew L. Albert
Institut Pasteur, Paris, France

Ajjai Alva
University of Michigan, Ann Arbor, USA

Andrea B. Apolo
National Cancer Institute, Rockville, USA

Jessie Au
Optimum Therapeutics, LLC, Columbus, USA

Marko Babjuk
Motol University Hospital and 2nd Faculty of Medicine, Prague, Czech Republic
 
Rick Bangs
Patient Advocate, Rochester Hills, USA

Trinity Bivalacqua
Johns Hopkins Medicine, Baltimore, USA

Peter Black
University of British Columbia, Vancouver, Canada

Bernard Bochner
Memorial Sloan-Kettering Cancer Center, New York, USA

James Catto
The University of Sheffield, Sheffield, United Kingdom

Karim Chamie
University of California Los Angeles, Los Angeles, USA

Keith Syson Chan
Baylor College of Medicine, Houston, USA

Sam S. Chang
Vanderbilt University Medical Center, Nashville, USA

Liang Cheng
Indiana University, Indianapolis, USA

Richard J. Cote
University of Miami Miller School of Medicine, Miami, USA

Bogdan Czerniak
University of Texas, Austin, USA

Siamak Daneshmand
University of Southern California, Los Angeles, USA

Ian D. Davis
Monash University and Eastern Health, Melbourne, Australia

Colin P.N. Dinney
University of Texas MD Anderson Cancer Center, Houston, USA

Lars Dyrskjøt
Aarhus University, Aarhus, Denmark 

Thomas Flaig
University of Colorado, Boulder, USA 

Scott M. Gilbert
H. Lee Moffitt Cancer Center & Research Institute, Tampa, USA

John Gore
University of Washington, Seattle, USA

Susan Groshen
University of Southern California, Los Angeles, USA

Noah Hahn
Johns Hopkins University School of Medicine, Baltimore, USA

Richard Hautmann
Universität Ulm, Ulm, Germany
 
Jean Hoffman-Censits
Thomas Jefferson University, Philadelphia, USA

Molly A. Ingersoll 
Institut Pasteur, Paris, France

Ashish M. Kamat
University of Texas, Austin, USA

Lawrence Karsh
The Urology Center of Colorado, Denver, USA

Wassim Kassouf
McGill University Health Center, Montreal, Canada

Lambertus (Bart) Kiemeney
Radboud University Medical Center, Nijmegen, The Netherlands

Anne Kiltie
University of Oxford, Oxford, United Kingdom

William Kim
University of North Carolina, Chapel Hill, USA

Margaret Knowles
University of Leeds, Leeds, United Kingdom

Badrinath Konety
University of Minnesota, Minneapolis, USA

David J. Kwiatkowski
Harvard Medical School, Boston, USA

Donald Lamm
University of Arizona, Phoenix, USA

David Latini
Baylor College of Medicine, Houston, USA

Nathan Lawrentschuk
University of Melbourne, Victoria, Australia

Vinata Lokeshwar
University of Miami, Miami, USA

Yair Lotan
UT Southwestern Medical Center, Dallas, USA 

Nuria Malats
CNIO, Madrid, Spain

Surena F. Matin
University of Texas MD Anderson Cancer Center, Houston, USA

Kazumasa Matsumoto
Kitasato University, Kanagawa, Japan 

James McKiernan
Columbia University, New York, USA

Maxwell Meng
University of California San Francisco, San Francisco, USA

Anirban P. Mitra
University of Southern California, Los Angeles, USA

Ofer Nativ
Bnai Zion Medical Center, Haifa, Israel

Hiroyuki Nishiyama
University of Tsukuba, Tsukuba, Japan

Tim O'Brien
Guy’s and St Thomas’, London, United Kingdom

Michael A. O'Donnell
University of Iowa Carver College of Medicine, Iowa City, USA

Howard L. Parnes
National Cancer Institute, NIH, Bethesda, USA

Dan Petrylak
Yale University, New Haven, USA

Elizabeth R. Plimack
Fox Chase Cancer Center, Philadelphia, USA

Kamal Pohar
Ohio State University, Columbus, USA

Michael P. Porter
University of Washington, Seattle, USA

David Quinn
University of Southern California, Los Angeles, USA

Derek Raghavan
Levine Cancer Institute, Charlotte, USA

Joan Palou Redorta
Universitat Autónoma de Barcelona, Barcelona, Spain

Cyrill Rentsch
University Hospital of Basel, Basel, Switzerland 

Bas W.G. van Rhijn
Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands

Jonathan Rosenberg
Memorial Sloan-Kettering Cancer Center, New York, USA

Arthur I. Sagalowsky
UT Southwestern, Dallas, USA

Maria De Santis
Kaiser-Franz-Josef-Spital, Vienna, Austria

Bernd J. Schmitz-Dräger
Department of Urology, Schön Klinik Nürnberg Fürth, Fürth, Germany

Mark P. Schoenberg
The Albert Einstein College of Medicine & The Montefiore Medical Center, New York, USA

Shahrokh F. Shariat
Medical University Vienna, Vienna, Austria

Eila C. Skinner
Stanford University, Stanford, USA

Carolyn Smith
Baylor College of Medicine, Houston, USA

Norm Smith
University of Chicago, Chicago, USA

Walt Stadler
University of Chicago, Chicago, USA

Gary Steinberg
University of Chicago, Chicago, USA

Arnulf Stenzl
Universitätsklinikum Tübingen, Tübingen, Germany

Seth Strope
Washington University, St. Louis, USA

Robert Svatek
UT Health Science Center San Antonio, San Antonio, USA

Antonia Vlahou
Biomedical Research Foundation Academy of Athens, Athens, Greece

Nick Vogelzang
Comprehensive Cancer Centers of Nevada, Las Vegas, USA

J. Alfred Witjes
Radboud University Nijmegen, Nijmegen, The Netherlands

Statistical and Bioinformatics Editorial Board

Edward J. Bedrick
University of Colorado, Aurora, USA

Debashis Ghosh
University of Colorado, Aurora, USA

Michael C. Sachs
NIH, Bethesda, USA

Richard Sylvester
EORTC, Brussels, Belgium

Jeremy Taylor
University of Michigan, Ann Arbor, USA

SUBMISSION OF MANUSCRIPT

Authors are requested to submit their manuscript electronically to the journal’s editorial management system.

Note that the manuscript should be uploaded as one file with tables and figures included. This file can be a Word document, a PDF, or an embedded zip file (.rar) if separate high resolution figures or a supplemental file such as a video are also to be included with the submission (the file size maximum for a video is 25MB). If the video is too large to submit, please contact blc@iospress.com to arrange a file transfer. For more information about submitting supplementary data see “Supplementary Data.”

Resubmissions should include the manuscript number in the cover letter. Resubmissions should clearly mention that the submission is a Revision and include the reference number in the submission letter. The author's replies to the reviewer comments should be included in the revised manuscript itself (at the top). The revised paper should always be a Word document.

Submission of a Review paper should be clearly mentioned in the cover letter to help the editorial process.

Submission of an article is understood to imply that the article is original and unpublished and is not being considered for publication elsewhere. Any possible conflict of interest, financial or otherwise, related to the submitted work must be clearly indicated in the manuscript. Procedures involving experiments on human subjects should be in accord with the ethical standards of the Committee on Human Experimentation of the institution in which the experiments were done or in accord with the Helsinki Declaration of 1975. Procedures involving experimentation on animal subjects should be in accord with either the guide of the institution in which the experiments were done, or with the National Research Council’s guide for the care and use of laboratory animals.

If the address to which proofs should be sent is different from the correspondence address, authors are kindly requested to indicate this. Both the editor and the publisher should be informed of any changes in either or both of these addresses. Please also supply a direct telephone number and a fax number, if available.

PREPARATION OF MANUSCRIPTS

Research Reports

Organization and style of presentation
1. Manuscripts must be written in English. Authors whose native language is not English are recommended to seek the advice of a native English speaker, if possible, before submitting their manuscripts. You can also visit www.internationalscienceediting.com. International Science Editing offers a language and copyediting service to all scientists who want to publish their manuscript in scientific peer-reviewed periodicals and books.

2. Manuscripts should be double spaced throughout with wide margins (2.5cm or 1in), including the abstract and references. Every page of the manuscript, including the title page, references, tables, etc., should include a page number centered at the bottom.

3. Manuscripts should be organized in the following order with headings and subheadings typed on a separate line, without indentation.

Title page
- Title (should be clear, descriptive and concise)
- Full name(s) of author(s)
- Full affiliation(s). Delineate affiliations with lowercase letters.
- Present address of author(s), if different from affiliation
- Running title (45 characters or less, including spaces)
- Complete correspondence address, including telephone number, fax number and email address

Leave the author information blank if double-blind peer review is wished for, but do include the information in the cover letter.

Abstract and Keywords
-The abstract for research papers should follow the "structured abstract" format:
BACKGROUND: 
OBJECTIVE:
METHODS: 
RESULTS:
CONCLUSIONS:
The abstract should try to be no longer than 250 words.
- For other papers such as Reviews, the abstract should be clear, descriptive, and self-explanatory, and no longer than 250 words.
- Include a list of 4-10 keywords. These keywords should be terms from the MeSH database.

Introduction

Materials and Methods

Results

Discussion

Acknowledgments including sources of support

Conflict of Interest
If there is no conflict of interest to declare, do still include this section and insert "The authors have no conflict of interest to report".

References
- Place citations as numbers in square brackets in the text. All publications cited in the text should be presented in a list of references following the text of the manuscript. Only articles published or accepted for publication should be listed in the reference list. Submitted articles can be listed in the text as (author(s), unpublished data).
- All authors should be listed in the reference list.
- References must be listed in Vancouver style:

[1] Rose ME, Huerbin MB, Melick J, Marion DW, Palmer AM, Schiding JK, Kochanek PM, Graham SH. Regulation of interstitial excitatory amino acid concentrations after cortical contusion injury. Brain Res. 2002; 935(12): 406-416.
[2] Murray PR, Rosenthal KS, Kobayashi GS, Pfaller MA. Medical microbiology. 4th ed. St. Louis: Mosby; 2002.
[3] Berkow R, Fletcher AJ, editors. The Merck manual of diagnosis and therapy. 16th ed. Rahway (NJ): Merck Research Laboratories; 1992.
[4] Meltzer PS, Kallioniemi A, Trent JM. Chromosome alterations in human solid tumors. In: Vogelstein B, Kinzler KW, editors. The genetic basis of human cancer. New York: McGrawHill; 2002. p. 93113.
[5] Canadian Cancer Society [homepage on the Internet]. Toronto: The Society; 2006 [updated 2006 May 12; cited 2006 Oct 17]. Available from: http://www.cancer.ca/.

Tables
- Number according to their sequence in the text. The text should include references to all tables.
- Provide each table on a separate page of the manuscript after the references.
- Include a brief and self-explanatory title with any explanations essential to the understanding of the table given in footnotes at the bottom of the table.
- Vertical lines should not be used to separate columns. Leave some extra space between the columns instead.

Figure Legends

Figures
Number the figures according to their sequence in the text. The text should include references to all figures.
- Figures should preferably be formatted in TIF or EPS format. JPG is also acceptable.
- Figures should be designed with the format of JHD in mind and preferable sized as they will appear when printed. A single column of the journal is 77mm and two columns are 165mm.
- Figures should be at 300 dpi or higher and be cropped to include the figure only (no blank space). CMYK is preferred for color figures.
- On figures where a scale is needed, use bar scales to avoid problems if the figure needs to be reduced.
- Each illustration should have a brief self-explanatory legend that should be typed separately from the figure in the section of the manuscript following the tables.
- Costs for color figures in the print version of the journal are as follows: 1 figure - 650 euro; 2 figures - 900 euro; 3 figures - 1050 euro; 4 figures - 1200 euro; 5 figures - 1350 euro. Cost for each additional color figure will be 150 euro. Color figures are free in the electronic version of the journal. You may opt to send in both black/white figures for print, and color figures for the online PDF (please adjust the figure legend appropriately).

Supplementary Data
Supplementary data can be submitted with the manuscript, inserted at the end of the document. Legends should be included for each item. Each supplementary item should not exceed the file size of 10MB. Supplemental videos can also be submitted (see top of page), and a title and legend should be included as Supplementary Material within the manuscript. Large datasets should be hosted on the author’s own or institute’s website or in an appropriate database.

Reviews
Reviews should be authoritative and topical and provide comprehensive and balanced coverage of a timely and/or controversial issue. Reviews should be prepared as detailed above for a Research Report, omitting Introduction through Discussion, and include a conclusion.

Short Communications
A short communication is an article of original scholarship of unusual interest of less than 1500 words (not including references). An abstract of 100 words or less should be included with no subdivison of text into sections. References should be formatted as above. A total of two tables and/or figures are allowed.

Hypotheses
A hypothesis article should be a balanced and insightful consideration of a topic with novel hypotheses well presented and supported. The article should be prepared as a Research Report but without Methods or Results sections.

Case Reports
Clinical case reports will be considered for publication, but they should feature some novelty, such as improving our understanding of a pathomechanism.

Book Reviews
Book reviews should be 750 words or less and without sections. Suggestions can be proposed to the Editors-in-Chief.

Letters to the Editor
Authors can submit comments of 1000 words or less concerning prior articles published in BLC to the Editors-in-Chief through the Editorial Office.

Commentaries
Commentaries can be around 1000 words with an abstract and no other subdivisions.

REMEMBER TO INCLUDE

In cover letter:
Name, postal address, phone number, fax number and e-mail address of the corresponding author.
- Name of an Associate Editor with expertise in the area of the study (if no Associate Editor is suitable, the Editorial Office will handle the submission).
- Statement that all authors have contributed to the work, agree with the presented findings, and that the work has not been published before nor is being considered for publication in another journal.
- A list of at least 4-6 potential reviewers knowledgeable in the area of the study and potential reviewer conflicts.
- Statement that procedures involving experiments on human subjects are done in accord with the ethical standards of the Committee on Human Experimentation of the institution in which the experiments were done or in accord with the Helsinki Declaration of 1975. 
- Statement that procedures involving experimentation on animal subjects are done in accord with either the guide of the institution in which the experiments were done, or with the National Research Council's guide for the care and use of laboratory animals.

In manuscript:
Compliance with guidelines on human experimentation as well as protocol approval by a local Institutional Review Board should be specified.
- Compliance with guidelines of animal experimentation as well as protocol approval by the Institutional Animal Care and Use Committee should be specified.
- Statement of all financial and material support for this research and any potential conflicts should also be clearly identified in the the acknowledgment and Conflict of Interest sections. If there is no Conflict-of-Interest then still add this statement.

Resubmissions
Resubmissions should include the manuscript number and a reference that the paper is a revision. The point-by-point response to the previous reviews should be included at the top of the manuscript. 

Financial Disclosure
All affiliations with or financial involvement (e.g., employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, royalties) with any organization or entity with a financial interest in or in financial competition with the subject matter or materials discussed in the manuscript are completely disclosed in the letter of submission.

All financial and material support for this research and work are clearly identified in the manuscript including listing of support specified in the letter of submission that might constitute or give the appearance of influencing the findings, based on the judgment of the Editor-in-Chief in consultation with the Associate Editor handling the review of the manuscript.

Policy regarding the NIH Public Access Policy mandate (PubMed Central)
IOS Press grants authors permission to supply their own version of the article (not the published PDF version) to PubMed Central, at no charge.

Alternatively, the author can submit the final published version of the article, which can be ordered from IOS Press. This service costs US$120 / €100 and an order form will be sent with the galley proof of the article to the corresponding author.

Orders for a pdf of published articles can also be sent to order@iospress.nl.

Authors who have paid the Article Processing Charges (APCs) for Open Access may freely deposit the final pdf.

The guidelines for PubMed Central submission can be found here. Submission Method C.

This policy is also applicable to European Pubmed Central submissions.

PRE-PRESS AND PROOFS

Accepted articles will be placed online as "pre-press" articles shortly after acceptance. This process will occur before the author receives proofs. The pre-press file will remain as the uncorrected proof version until the article is published in an issue and the final published version replaces the pre-press file.

The corresponding author will receive a pdf proof and is asked to check this proof carefully (the publisher will execute a cursory check only). Corrections other than printer's errors, however, should be avoided. Costs arising from such corrections will be charged to the authors.

OPEN ACCESS OPTION

The IOS Press Open Library® offers authors an Open Access (OA) option. By selecting the OA option, the article will be freely available from the moment it is published, also in the pre-press module. In the Open Library® the article processing charges are paid in the form of an Open Access Fee. Authors will receive an Open Access Order Form upon acceptance of their article. Open Access is entirely optional. See also our website for more information about this option IOS Press Open Library®.

COPYRIGHT

Copyright of your article
Authors submitting a manuscript do so on the understanding that they have read and agreed to the terms of the IOS Press Author Copyright Agreement.

Quoting from other publications
An author, when quoting from someone else's work or when considering reproducing figures or table from a book or journal article, should make sure that he is not infringing a copyright. Although in general an author may quote from other published works, he should obtain permission from the holder of the copyright if he wishes to make substantial extracts or to reproduce tables, plates or other figures. If the copyright holder is not the author of the quoted or reproduced material, it is recommended that the permission of the author should also be sought. Material in unpublished letters and manuscripts is also protected and must not be published unless permission has been obtained. Submission of a paper will be interpreted as a statement that the author has obtained all the necessary permission. A suitable acknowledgement of any borrowed material must always be made.

COMPLIMENTARY COPY AND PURCHASE

Complimentary copy
The corresponding author of a contribution to the journal is entitled to receive 1 author’s copy of the pdf free of charge, unless otherwise stated. Free copies will not be provided for conference proceedings and abstract issues.

How to order reprints, a pdf file, journals, or IOS Press books
An order form for reprints, additional journal copies or a non-watermarked pdf file will be provided along with the pdf proof.
If you wish to order reprints of an earlier published article, please contact the publisher for a quotation. IOS Press, Fax: +31 20 6870039. Email: editorial@iospress.nl.

An author is entitled to 25% discount on IOS Press books. See Author's Discount (25%) on all IOS Press book publications.